

## Aerocrine applies for delisting

**The Board of Directors of Aerocrine AB (publ) (“Aerocrine”) has decided to apply for the delisting of the Aerocrine share from Nasdaq Stockholm. The last day of trading in the share is expected to be July 13, 2015.**

On June 15, 2015, Circassia Pharmaceuticals plc (“Circassia”) announced that the public offer to the shareholders of Aerocrine had been accepted to such an extent that Circassia now holds 92.6 percent of the shares and votes in Aerocrine. Circassia also announced its intention to request compulsory buy-out (tvångsinlösen) of the remaining shares in Aerocrine. In light of this, Aerocrine’s Board of Directors concludes that it is no longer justified for the company to remain listed and therefore has resolved to apply for the delisting of the Aerocrine share from Nasdaq Stockholm. The last day of trading in the Aerocrine share on Nasdaq Stockholm is expected to be July 13, 2015.

### **For more information, contact:**

Jenny Rosberg, IR/PR, ROPA, Phone +46 70 747 27 41

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Marshall Woodworth, Chief Financial Officer, Aerocrine AB, Phone: +1 919 749 8748

### **About Aerocrine**

*Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which enables fast and reliable point-of-care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit [www.aerocrine.com](http://www.aerocrine.com) and [www.niox.com](http://www.niox.com).*

Aerocrine is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 3:45 pm CET June 26, 2015.